1
|
Martins AD, Panner Selvam MK, Agarwal A, Alves MG, Baskaran S. Alterations in seminal plasma proteomic profile in men with primary and secondary infertility. Sci Rep 2020; 10:7539. [PMID: 32372034 PMCID: PMC7200760 DOI: 10.1038/s41598-020-64434-1] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2020] [Accepted: 04/06/2020] [Indexed: 02/06/2023] Open
Abstract
Proteome of seminal plasma provides profound information related to the male reproductive health. This pilot study was conducted to characterize proteomic profile of seminal plasma from men with primary, or secondary infertility and compare it with proven fertile men. Study participants (n = 59) were recruited at the Cleveland Clinic and divided according to their fertility status: proven fertile (n = 39); primary infertility (n = 11) and secondary infertility (n = 9). Proteomic shotgun analysis revealed a total of 515 peptides common to primary infertility and control group; whereas 523 peptides were common to secondary infertility and control group. Bioinformatic analysis revealed dysregulation of biological processes such as cell secretion and vesicle mediated transport in primary infertility, whereas immune system response, regulation of proteolysis and iron homeostasis were dysregulated in secondary infertility. Western blot validation showed overexpression of ANXA2 and CDC42, and underexpression of SEMG2 proteins in primary infertility; and overexpression of ANXA2 and APP proteins in secondary infertility. This study elucidates the potential role of differentially expressed proteins in the seminal plasma as diagnostic biomarker for primary and secondary infertility. Furthermore, our results suggest maturation failure and immune reaction response as the main cause of infertility in men with primary and secondary infertility, respectively. Additional validation of the proteins involved in the above pathways is warranted.
Collapse
Affiliation(s)
- Ana D Martins
- American Center for Reproductive Medicine, Cleveland Clinic, Cleveland, OH, USA
- Department of Microscopy, Laboratory of Cell Biology, Institute of Biomedical Sciences Abel Salazar and Unit for Multidisciplinary Research in Biomedicine, University of Porto, Porto, Portugal
| | | | - Ashok Agarwal
- American Center for Reproductive Medicine, Cleveland Clinic, Cleveland, OH, USA.
| | - Marco G Alves
- Department of Microscopy, Laboratory of Cell Biology, Institute of Biomedical Sciences Abel Salazar and Unit for Multidisciplinary Research in Biomedicine, University of Porto, Porto, Portugal
| | - Saradha Baskaran
- American Center for Reproductive Medicine, Cleveland Clinic, Cleveland, OH, USA
| |
Collapse
|
2
|
Cheng M, Sun X, Liu G, Cheng K, Lv Z, Sun C, Xiu D, Liu L. Comprehensive analysis of marker gene detection and computed tomography for the diagnosis of human lung cancer. Oncol Lett 2018; 16:4400-4406. [PMID: 30250539 PMCID: PMC6144882 DOI: 10.3892/ol.2018.9211] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2017] [Accepted: 03/09/2018] [Indexed: 12/23/2022] Open
Abstract
Non-small cell lung cancer (NSCLC) is one of leading causes of cancer-associated mortality, with a high number of cases caused by metastasis. The early diagnosis of cancer contributes to the successful treatment of patients with lung cancer. The aim of the present study was to analyze the efficacy of marker gene detection and computed tomography (CT) in diagnosing human lung cancer. Lung cancer marker genes, including carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), tissue polypeptide antigen (TPA), pro-gastrin-releasing peptide (ProGRB), cytokeratin fragment 21-1 (Cyfra21-1) and neuron-specific enolase (NSE), were analyzed in patients with lung cancer. The tumor size was evaluated using CT, and the association between lung serum levels of marker gene protein expression and tumor size was investigated. A total of 328 patients with lung cancer were identified, including 204 adenocarcinoma, 75 large cell carcinoma and 49 squamous cell carcinoma cases. All patients were indicated to have a high serum level of CEA, CA125, TPA, ProGRB, Cyfra21-1 and NSE, compared with the normal range. Immunohistochemistry demonstrated higher expression levels of CEA, CA125, TPA, ProGRB, Cyfra21-1 and NSE in lung tumor tissues, compared with the normal range. Results indicated that CT was able to diagnose tumor size for patients with lung cancer. The CEA and CA125 expression levels were associated with CT-diagnosed adenocarcinoma tumor size. Large cell carcinoma tumor size was associated with serum levels of CEA, TPA and ProGRB. Results indicated that Cyfra21-1 and NSE were associated with the squamous cell carcinoma cases, as demonstrated using CT. In conclusion, these results indicated that comprehensive analysis of marker gene detection and CT results may be used to diagnose human lung cancer.
Collapse
Affiliation(s)
- Min Cheng
- Department of Radiology, Jilin University, China Japan Union Hospital, Changchun, Jilin 130033, P.R. China
| | - Xiaosong Sun
- Department of Head and Neck Surgery, Jilin Cancer Hospital, Changchun, Jilin 130000, P.R. China
| | - Guifeng Liu
- Department of Radiology, Jilin University, China Japan Union Hospital, Changchun, Jilin 130033, P.R. China
| | - Kailiang Cheng
- Department of Radiology, Jilin University, China Japan Union Hospital, Changchun, Jilin 130033, P.R. China
| | - Zhongwen Lv
- Department of Radiology, Jilin University, China Japan Union Hospital, Changchun, Jilin 130033, P.R. China
| | - Changjiang Sun
- Department of Radiology, Jilin University, China Japan Union Hospital, Changchun, Jilin 130033, P.R. China
| | - Dianhui Xiu
- Department of Radiology, Jilin University, China Japan Union Hospital, Changchun, Jilin 130033, P.R. China
| | - Lin Liu
- Department of Radiology, Jilin University, China Japan Union Hospital, Changchun, Jilin 130033, P.R. China
| |
Collapse
|
3
|
Tanase CP, Codrici E, Popescu ID, Mihai S, Enciu AM, Necula LG, Preda A, Ismail G, Albulescu R. Prostate cancer proteomics: Current trends and future perspectives for biomarker discovery. Oncotarget 2017; 8:18497-18512. [PMID: 28061466 PMCID: PMC5392345 DOI: 10.18632/oncotarget.14501] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2016] [Accepted: 12/27/2016] [Indexed: 02/07/2023] Open
Abstract
The clinical and fundamental research in prostate cancer - the most common urological cancer in men - is currently entering the proteomic and genomic era. The focus has switched from one single marker (PSA) to panels of biomarkers (including proteins involved in ribosomal function and heat shock proteins). Novel genetic markers (such as Transmembrane protease serine 2 (TMPRSS2)-ERG fusion gene mRNA) or prostate cancer gene 3 (PCA3) had already entered the clinical practice, raising the question whether subsequent protein changes impact the evolution of the disease and the response to treatment. Proteomic technologies such as MALDI-MS, SELDI-MS, i-TRAQ allow a qualitative/quantitative analysis of the proteome variations, in both serum and tumor tissue. A new trend in prostate cancer research is proteomic analysis of prostasomes (prostate-specific exosomes), for the discovery of new biomarkers. This paper provides an update of novel clinical tests used in research and clinical diagnostic, as well as of potential tissue or fluid biomarkers provided by extensive proteomic research data.
Collapse
Affiliation(s)
- Cristiana Pistol Tanase
- Department of Biochemistry-Proteomics, Victor Babes National Institute of Pathology, Bucharest, Romania
- Titu Maiorescu University, Faculty of Medicine, Bucharest, Romania
| | - Elena Codrici
- Department of Biochemistry-Proteomics, Victor Babes National Institute of Pathology, Bucharest, Romania
| | - Ionela Daniela Popescu
- Department of Biochemistry-Proteomics, Victor Babes National Institute of Pathology, Bucharest, Romania
| | - Simona Mihai
- Department of Biochemistry-Proteomics, Victor Babes National Institute of Pathology, Bucharest, Romania
| | - Ana-Maria Enciu
- Department of Biochemistry-Proteomics, Victor Babes National Institute of Pathology, Bucharest, Romania
- Department of Cell Biology and Histology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
| | - Laura Georgiana Necula
- Department of Biochemistry-Proteomics, Victor Babes National Institute of Pathology, Bucharest, Romania
- Stefan S Nicolau Institute of Virology, Bucharest, Romania
| | - Adrian Preda
- Center for Uronephrology and Renal Transplantation, Fundeni Clinical Institute, Bucharest, Romania
| | - Gener Ismail
- Center of Internal Medicine-Nephrology, Fundeni Clinical Institute, Bucharest, Romania
- Carol Davila University of Medicine and Pharmacy, Faculty of Medicine, Bucharest, Romania
| | - Radu Albulescu
- Department of Biochemistry-Proteomics, Victor Babes National Institute of Pathology, Bucharest, Romania
- National Institute for Chemical Pharmaceutical R&D, Bucharest, Romania
| |
Collapse
|